Shopping Cart
- Remove All
- Your shopping cart is currently empty
B7-H3 Protein, Human, Recombinant (His), AF647-Labeled is expressed in HEK293 Cells. The accession number is Q5ZPR3-1.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 μg | $539 | Backorder | |
100 μg | $1,730 | Backorder |
Biological Activity | 1. Flow cytometric analysis of anti-B7-H3 CAR expression. 293 cells were lentivirally transduced with anti-B7-H3 CAR. Flow cytometric analysis was performed with a negative control protein and B7-H3 Protein, Human, Recombinant (His), AF647-Labeled (Cat#TMPY-07060), respectively. Non-transduced 293 cells were used as a control (left). 2. Binding activity of AF 647-conjugated B7-H3 protein to PBMC cells. PBMC cells were stained with anti-CD3 antibody and B7-H3 Protein, Human, Recombinant (His), AF647-Labeled (Cat#TMPY-07060) and detected by flow cytometry. PBMC cells stained with anti-CD3 antibody were used as a control (left). |
Description | B7-H3 Protein, Human, Recombinant (His), AF647-Labeled is expressed in HEK293 Cells. The accession number is Q5ZPR3-1. |
Species | Human |
Expression System | HEK293 Cells |
Tag | C-His |
Accession Number | Q5ZPR3-1 |
Synonyms | UNQ309/PRO352,PSEC0249,B7RP-2,B7-H3,B7H3,4Ig-B7-H3 |
Construction | A DNA sequence encoding the extracellular domain (Met 1-Thr 461) of human B7-H3 (Q5ZPR3-1) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 647 (Excitation Max.= 655 nm, Emission Max.= 680 nm). |
Protein Purity | ≥ 90% as determined by SDS-PAGE. |
Molecular Weight | 50 kDa (predicted) |
Endotoxin | < 1.0 EU per μg protein as determined by the LAL method. |
Formulation | This product is Lyophilized from sterile PBS, 5% Trehalose, 5% Mannitol, pH 7.4. Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
Reconstitution | Please refer to the lot-specific COA. |
Stability & Storage | Twelve months from date of receipt at -20℃ to -70℃ in lyophilized form and 3 months at -70℃ under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles. |
Shipping | In general, Lyophilized powders are shipping with blue ice. |
Research Background | B7-H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co-inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7-H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IP AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.